FDA Flags Eli Lilly's Weight-Loss Drug Video For Misleading Claims

Core Points - The FDA has determined that a promotional video for Zepbound and Mounjaro is false or misleading, underplaying serious health risks and omitting critical safety information [1][3][4] - Eli Lilly's stock is experiencing a steady increase despite the FDA's findings, with shares up 2.38% at $766.02 [7] Group 1: FDA Findings - The video, hosted by Oprah Winfrey, featured paid consultants who discussed the benefits of Zepbound and Mounjaro but did not adequately disclose significant risks [2][5] - The FDA cited violations of the Federal Food, Drug, and Cosmetic Act, including the failure to reveal critical information and minimizing potential side effects [4][6] - Both drugs carry boxed warnings for life-threatening risks, including thyroid C-cell tumors, which were not sufficiently highlighted in the video [3][6] Group 2: Eli Lilly's Response - Eli Lilly has 15 working days to respond to the FDA's findings and stated that the FDA's letter pertains to interviews conducted by independent media outlets, over which it had no editorial control [7]